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 Highlights: 
• Relatively little attention is given in the health economics literature to the valuation of temporary 
health states. 
• Complications associated with the valuation of temporary health states have  previously been the 
reason given for the use of cost-effectiveness analysis rather than cost-utility analysis (preferred 
by many decision-making bodies) for evaluation in contexts such as sexual health.  
• Although many studies reviewed suggested that chained standard gamble and time trade-off 
would be the ideal approaches for temporary health state valuation, they were often not used due 
to fears around the cognitive and time burden on respondents. 
• Where chained approaches were used they, they were found to be feasible, less susceptible to 
bias and able to detect minimal changes in health states. 
• Future research should focus on anchoring for chained standard gamble and time trade-off. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 ABSTRACT 
Objective: A broad literature on health state utility values (HSUVs) exists, but compared with chronic 
health states, issues surrounding the valuation of temporary health states have been poorly explored. 
This review aimed to assess the methods used by previous studies to value health states that are 
considered temporary, in order to determine the strengths and limitations associated with various 
approaches and inform future study designs.  
Methods: A systematic review was undertaken to explore the methods used, assess how the valuation 
was conducted for diseases that might lead to health states deemed as temporary and identify the 
challenges encountered in the valuation of temporary health states.  
Results: Of the 36 relevant studies, 22 were explicit that the health state being valued was temporary. 
Most of the studies used more than one technique (often incorporating both conventional and adapted 
approaches). In using adapted techniques, the primary challenge was identifying an appropriate 
intermediate ‘anchor’ health state and the possibility of negative utilities.  
Conclusions: There is no agreement on the most methodologically robust approach to valuing temporary 
health states. Valuation is complex and important issues relating to the validity, practicality and reliability 
of the techniques used, were not adequately covered by  most of the studies identified.   
Keywords: Health State Utility Values, Temporary Health States, Systematic Review 
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INTRODUCTION 
Economic evaluations are conducted to provide evidence on the cost-effectiveness of interventions and 
inform decisions on the allocation of scarce healthcare resources [1]. In many countries, including the 
United Kingdom (UK), decision-making bodies require interventions to be evaluated using quality-
adjusted-life-years (QALYs) [2,3].  QALYs combine changes in quality-of-life (QoL) – reflecting individuals’ 
relative preferences for health states (HS) and life-expectancy [4,5]. HS valuation studies assign 
numerical values known as health state utility values (HSUVs) to HS descriptions and they are essential 
to allow economic evaluations to be undertaken [6,7].  
The methodology for valuing chronic HS has been discussed extensively [8-12]. A broad literature exists 
on HSUV estimates for a diverse range of chronic conditions, including obstructive lung diseases [13], 
diabetes [14,15], chronic mental illnesses [16-18] and musculoskeletal disorders [19,20], that can be 
incorporated into economic evaluations [6]. However, for some clinical conditions such as pregnancy-
related complications [21-24] and sexually transmitted infections (STIs) [25-27], preference-based 
measurements for HSUVs are less widely researched or are perceived as more challenging [25,28,29], 
possibly because these conditions involve temporary health states (THS) [30]. It has been noted, for 
example, that in the economic literature on STIs, most studies report results in terms of cost per major 
outcome averted, because no robust values for QALYs exist [31-33]; those who have highlighted this 
trend cite the temporary nature of the HS as one of the key complicating factors.  
In contrast to chronic HS whose durations are individuals’ life-expectancies [34], THS are states 
described as lasting for a specified length of time (weeks, months or years), followed by a return to full 
health [30,34]. It has been argued that conventional approaches to valuing outcomes or measuring QoL 
such as Time trade-off (TTO), Standard gamble (SG) and Visual analogue scale (VAS) are not 
appropriate for such HS due to their underlying assumptions [35]. There are techniques designed 
specifically for THS valuation, which are adapted from the conventional methods (Box 1). These include 
chained approaches for TTO and SG, waiting time trade-off (WTO), and sleep trade-off.  There is 
currently no ‘gold standard’ [30] from this range of possible approaches, and THS valuation has been 
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discussed less comprehensively in the literature [25,30,36]. Studies that have assessed THS have not 
always been explicit about the fact that the HS being valued is of temporary nature [26,27].  
This paper reports findings from a systematic review of studies that valued diseases/conditions where the 
resulting HS can be defined as temporary. Two principal questions were explored, 1) what 
methodological approach was undertaken in the valuation of the HS, and 2) how was the tension between 
the temporary and chronic health components of the HS resolved or addressed? In this paper, THS is 
defined as any health condition which causes some impairment to QoL, lasting for a duration of one year 
or less, after which there is return to normal health [30]. For the purposes of this review we identified 
studies that either explicitly described the HS under consideration as temporary or where the reviewers 
assessed that the nature of the diseases or HS being considered is of a temporary nature. Thus even if 
the authors of the papers used a time period in the valuation exercise of longer than one year, it was still 
included in the review if the reviewers assessed the HS under consideration to be temporary based on 
the nature of the disease/HS. 
By answering these questions, the review will help to identify an appropriate approach for the valuation of 
THS. The outcomes will inform the literature on the methods that should be used for estimating HSUVs 
and improve the robustness of the data used in economic evaluations involving THS.  
 
METHODS 
The review followed the guidelines of the UK Centre for Review and Dissemination (CRD) [43] and is 
reported following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines [44].   
Inclusion criteria 
Papers published in English were included if the disease involved a THS, and the study included the 
valuation of THS. There was no design and year restriction in order to capture as many studies as 
possible and explore a range of methods.  Studies were excluded if they were editorials, reviews or 
economic evaluations based on secondary data, or if they reported on HS valuations that did not include 
any HS which could be viewed as temporary. 
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Search Strategy 
The following seven databases were searched: MEDLINE, Web of Science, EMBASE, Applied Social 
Sciences Index and Abstracts (ASSIA), ProQuest (minus ASSIA), NHS Economic Evaluation Database 
and Health Management Information Consortium (HMIC) (Appendix A). The reference lists of key papers 
were hand searched to identify other relevant studies. Where full texts of papers were unavailable, the 
study authors were contacted to request a copy. 
Information from the database search was managed using RefWorks [45]. Paper selection was 
conducted by all authors in two stages based on methods described elsewhere [25,46]. In stage 1, 
studies were screened and categorised on the basis of title, keywords and abstracts into seven groups (A 
to G) (Appendix B). For stage 2, the full texts of potentially relevant studies were read and classified 
further according to the methods adopted (Appendix C). 
Data extraction 
A data extraction form was used to extract data on study background, valuation method, participants and 
other relevant details. The information was tabulated to facilitate detailed data comparison.  
Analysis 
A narrative review was undertaken to summarize the evidence [43] and to compare results and methods 
across studies and the likely reasons for any inconsistencies. A formal quality appraisal was not carried 
out as there are no agreed criteria to appraise studies of this nature. However, to inform the analysis, we 
developed a framework based on an adapted version of a checklist reported by Brazier et al. [47,48]. 
Brazier et al.’s original checklist reviewed the application of the psychometric criteria of validity, 
practicality, and reliability of measures of health-related quality of life (HRQoL). Three of the criteria in the 
checklist were modified slightly to fit this study’s focus on THS valuation techniques, and an additional 
item was included to capture the issues associated with THS valuation (Box 2 ).  
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RESULTS 
Systematic search  
The database search identified 9,186 citations of which 3,449 were duplicates. A flow diagram of studies 
selected, excluded or retained is shown in Figure 1. Stage 1 of the categorisation (Appendix B) process 
led to the selection of 69 papers for further review. In the second stage of the process (Appendix C) 67 
studies classified as being in groups A, B and C were read in full and further categorised into six groups 
(1-6). Studies in groups A1, A2, B1, B2, and C1 (Appendices B and C) were selected for inclusion in the 
narrative synthesis as they focused on the valuation of THS and relevant data were extracted from these 
36 studies.   
Summary of selected studies 
The characteristics of the 36 studies are summarised and are presented in Tables 1 and 2.  Sixteen 
studies used data collected from respondents in the United States [26,27,39,41,49-60]. Eight studies 
were UK based [61-68], six were conducted in The Netherlands [69-74] and three in Canada [75-77]. Two 
of the studies were carried out in two or more countries [78,79], while one study was conducted in Spain 
[80]. The studies’ aims were diverse and included: the elicitation of HSUVs for specific conditions; 
assessing the feasibility and reliability of particular valuation techniques and comparing utilities among 
different populations. The HS covered by the papers were mostly related to treatments for various forms 
of cancers while two studies assessed pelvic inflammatory diseases (PID) [26,27].   
Valuation technique 
Twenty-two studies were explicit about the fact that the HS they were concerned with are THS . The 
remainder were not explicit but were judged to be concerned with the valuation of THS by the authors of 
this review (Table 2). Ten studies evaluated both chronic and temporary HS within a single study 
[26,27,50,53,57-59,61,62,66]. A variety of approaches were taken to accommodate this. Four papers 
used the same duration for all HS and applied the same technique justified on the basis of consistency 
[26,27,59,66]. Three papers used the same technique but adjusted the duration [58,61,62]. The remaining 
three used different techniques for different HS [50,53,57]. 
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 Thirty-one studies used more than one technique to value THS while only five used a single technique 
[39,57,61,62,64].  Overall, 12 papers used conventional methods such as SG and TTO to value THS 
[26,27,51,55,57,59-62,68,75,80]. Twenty-four papers used a variety of adapted methods which were 
specifically designed for THS. Twelve of these papers used the chained approach with TTO [63,73,79], 
SG [52,54,64,67,76,77] or both [65,70,72]. Eight studies used some modification of the conventional 
methods including SG  [78] and TTO [53,56,58,66,69,71,74]. Three of the studies used WTO [39,49,50], 
while one used sleep trade-off [41] (Table 1 ). 
Thirty studies specified the duration of the HS under consideration to the respondents. This ranged from 
two hours, for a study related to the side effects of chemotherapy in breast cancer patients [57], to 50 
years for a study assessing utilities for acute PID [27] (Table 2). Three studies did not state the HS 
duration they used [51,52.74].  
Justification for choice of method for THS 
Among the 12 studies that used conventional methods (typically applied to chronic HS), to value THS, 
only four justified their choice of approach (Table 2). Three of the studies used VAS and/or TTO because 
they felt it was easier [66], less tedious [80] and involved less cognitive burden [57] than the chained 
appoach. The fourth study, which used both VAS and SG stated that the methods were used because the 
chained SG is cumbersome [75] and I could mpose an additional response burden on participants. Badia 
et al. [80] argued that chained methods are more complicated and would increase study costs. 
Among the 24 studies that used adapted methods, 20 papers justified their choice. Five of the papers that 
used modified TTO and/or SG, cited the temporary nature of the HS being assessed [56,58,69,72] and 
the inappropriateness of classic conventional methods for THS valuation [74] as reasons for this.  Brazier 
et al [66] used a modification of TTO [81], because they felt that the chained approach was likely to 
generate biased estimates. For the remaining 13 papers in which the chained approach, WTO or Sleep 
trade-off were used, all cited the temporary or mild nature of the HS being assessed as reasons for 
adopting the technique.  
The second prevalent reason for using adapted techniques was to avoid the utilization of ‘dead’ as an 
anchor (five studies). In one case, the authors  [76] felt that some THS might be tolerable enough such 
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that the HS ‘dead’ would not be an acceptable alternative, while others-[64,67] believed that the mild and 
relatively healthy nature of the HS meant that ‘dead’ was an unfeasible end-point. Moreover, they felt that 
respondents would be reluctant to gamble between such mild HS and ‘dead’ [67]. Another study [77] went 
further and stated that they avoided the use of ‘dead’ because they aimed to enable decision-making that 
would be acceptable to those who valued life above all else.  
Three of the papers set out to assess the feasibility of the chained approach for THS valuation and hence 
focused on this method [54,70,73]. Johnston et al. [63] used the chained TTO because they felt that it 
was easier for participants than SG. 
Challenges associated with THS valuation 
Fourteen papers discussed the potential challenges associated with THS valuation (Table 2).  
Chained approaches 
Seven papers discussed the challenges encountered with the chained approach. A prevailing problem 
involved selecting a suitable intermediate (worst temporary) HS to use as an anchor in the first step of the 
chained approach. Johnston et al., [63] used chained TTO and found that despite carefully describing the 
intermediate HS, some respondents valued them as better than being in good health. Jansen et al., [70] 
used chained TTO and SG and also reported that some patients preferred the intermediate HS to some 
THS. This unexpected occurrence made the intermediate HS unsuitable for use in utility calculation for 
those respondents. In choosing an intermediate HS, Matza et al. [67] also reported that this was difficult 
due to differences in respondents’ risk aversion and their perception of the most severe THS.  
The second challenge associated with THS valuation was the possibility of negative utilities being 
assigned to some HS by respondents. For example, Jansen et al., [70] reported a zero valuation for the 
intermediate HS by 59% of the respondents for TTO and 36% of respondents for SG. This was echoed by 
Locadia et al. [73] who noted that if negatives values were allowed, some respondents’ HSUVs would 
have been less than zero. 
Some papers reported challenges in relation to the state of being ‘dead’ which was used in the second 
step of the chained approach [63,67,73].  One study, [63] found it difficult to value a THS on a scale that 
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included death in the short term, as respondents’ values were highly sensitive to the inclusion of death in 
the valuation question. Another study [73] found a downward bias (values converging at lower utilities) 
among respondents using a conventional TTO method and during the second stage of the chained TTO 
when they were told that the THS was followed by the dead state. 
Deciding on the absolute and relative durations to use for THS was challenging for one study [76]. The 
choice of duration is important as some papers reported that a relatively short duration could result in an 
upward bias (values converging at lower utilities) [67,73]. 
Modified techniques 
Two studies [56,66] modified the conventional method in terms of duration, and both stated that their 
respondents found it difficult to understand the TTO tasks. One of the studies [66] felt that the self-
completed format of their modified TTO was largely to blame for these difficulties.  
Waiting Time Trade-Off 
The three studies that utilised WTO to value THS highlighted several challenges with this method 
[39,49,50].  Firstly, for THS to be calculated, HSUVs for the condition of interest, or its absence or 
successful treatment are required [39]. Thus, the WTO studies, either did a literature search [50] or a 
primary study on patients using conventional TTO [39,49] to get these values. Secondly, the authors 
reported that WTO is suitable only for HS with a very short duration, as the utility values tend towards 
zero and negativity as the duration lengthens. Thirdly, the technique is difficult to apply in acute events 
and requires the presence of the disease symptoms for which the patient is being tested [49]. 
Conventional approaches 
Three of the papers that used conventional methods discussed the challenges they encountered. Badia 
et al. [80] reported participants’ reluctance to trade time in a worse HS, for time in a better HS, leading to 
many HS being assigned identical levels once aggregated and thereby invalidating the method. Smith et 
al., [26] used the conventional approach for chronic and THS and reported that the values generated for 
THS were not be ideal and that a chained approach would have been better. Finally, Dion et al., [75] used 
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VAS for THS valuation and SG for other HS and reported that, unexpectedly, some respondents found 
VAS more difficult than SG. 
Health state development 
The studies used a combination of approaches to develop HS descriptions. Most common was the use of 
expert opinion (23 studies), followed by literature reviews (15 studies) (Table 1). Only 12 studies used the 
experiences of patients, and five of them elicited patients’ experiences through focus group discussions 
(FGD) and in-depth interviews.  Three studies [61,62,80] selected HS from a subset of existing EQ-5D HS 
descriptors while one study [64] used previous guidelines. Nine of the papers were not explicit about how 
they developed HS descriptions for their studies. 
Validity, practicality, and reliability of studies  
The majority of the studies included in the review did not cover issues relating to the validity, practicality 
and reliability (Box 2) of the valuation techniques used in their reporting (Appendix D). 
Validity 
Among the studies that used more than one technique to value HS 22  included both choice based and 
non-choice based methods.  For the studies that used just one technique, three [39,64,66] used a choice 
based technique and two [57,62] utilised VAS, a non-choice based technique. 15 papers commented on 
the respondents’ understanding of the task, but only seven studies provided evidence to justify the points 
made. Five studies reported that they had evaluated respondents’ understanding by assessing the 
difficulty level of the exercise [41,65,70,71,80], task acceptability [77], or the number of outliers during 
their data analysis [60].  The respondents’ backgrounds were reported as representative of the population 
group being assessed in nearly all of the studies (30 out of 36 studies). Although 29 studies  presented a 
full description of the HS scenarios used, the remaining studies did not describe them in detail. The 
theoretical validity of the valuation techniques was discussed explicitly by just nine papers  
[49,51,58,63,64,71,72,77,80]. Only five papers that assessed empirical validity, with one [80] examining 
the number and proportion of inconsistencies between the original rank order respondents assigned to 
the HS and the ordering derived from the same HS from their valuations. 
Practicality 
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Twenty-six studies appraised the practicality of the techniques used in terms of the duration of the task, 
the response rate, and the completion rate. The time it took respondents to complete the task was 
reported by 11 papers. The response rate was reported by 17 of the selected papers. The data captured 
was assessed by 19 studies using the completion rate and/or the level of missing data. Fifteen studies 
presented details of the completion rate while two papers presented only the missing values [62,70] and  
another two [78,80] presented values for both the completion rate and the missing data.  
Reliability 
Among the six papers that reported on reliability, two [75,77] assessed the test-retest reliability, one [73] 
used correlation coefficient and two [41,71] stated that the techniques they had used were reliable but 
were not explicit about how they had reached this conclusion. One study used the TTO technique which 
they modified for duration and reported that they found the technique unreliable although no further 
details were included [56]. 
Discussion 
Summary of main findings 
The review identified and assessed studies that conducted valuations of THS in order to inform future 
economic evaluations involving such HS. Twenty-two studies highlighted themselves that some of the HS 
they were concerned with were temporary. The remaining 14 studies were deemed by the current authors 
to include the valuation of THS [Table 2]. Some studies that used conventional valuation methods 
included long durations for the valuation exercise [26,27,57,59,60,68]. Three acknowledged this as a 
limitation [26,27,59] and three justified this in that respondents would not trade off against death if they 
used a short duration in the valuation exercise [59,68,75]. However, four studies despite being explicit 
about the temporary nature of the conditions, and used adapted techniques, used a long duration 
[66,69,71,79] as they felt it represented a realistic life expectancy.   
In the literature on HS utilities valuation, trading-off time is not an integral component of the VAS 
technique but it is integral to the TTO and SG techniques. It was clear that the duration of the HS used 
with SG and TTO in the studies was not specified to respondents in the case of the VAS, except in a 
12 
 
small number of cases where authors explicitly. stated that this was the case [63,75]. A majority of the 
papers merely used the VAS as a warm-up task to familiarise the respondents with the HS descriptions. 
Thirty-one papers used more than one technique to conduct the valuation.  The majority of studies (24 of 
36) opted to use an adaptation of conventional methods of HS valuation due to the temporary nature of 
the HS of interest. The prevailing challenge in using the adapted techniques was the identification of an 
appropriate intermediate ‘anchor’ HS. Where the study included consideration of both temporary and 
chronic HS, a variety of approaches was adopted and there was no consensus amongst authors 
[26,27,50,57-59]. Although a number of studies used more than one method for valuation measurement, 
the prevalent technique, used by nearly all papers was VAS; this was typically used as a warm up or HS 
familiarisation exercise. and to identify the most appropriate HS to use as an anchor. The VAS is the least 
grounded in economic theory and does not involve any element of risk or uncertainty; hence it generates 
values and not utilities. [57].  
The commonest technique used by the papers for THS valuation was the chained approach. The majority 
of papers argued that either chained TTO or chained SG was the most appropriate technique for the 
valuation of THS. However, even though there was popular agreement on its appropriateness, 15  of the 
papers did not use it because of its perceived complexity and cost: it involves extra steps compared to the 
conventional methods However, other studies showed that the chained methods are feasible, less 
susceptible to bias and can detect minimal changes in HS [65,70]. They are seen as psychologically less 
threatening to respondents because the state of being dead is replaced by an intermediate HS [70]; this 
makes it more suitable for THS valuation where a return to normal health is common. There was a lack of 
consensus amongst study authors over the more appropriate of the two techniques, which reflects wider 
discussions in the literature [47]. Where both approaches were used in the same study [65,70], there was 
no systematic difference between them. It has been suggested that the technique chosen should reflect 
the situation which respondents are likely to encounter in reality, either a situation of risk (for SG) or 
certainty (for TTO) [65].  Furthermore, it has been proposed that when trading length of life against QoL, 
TTO is more appropriate, while in a situation where there is a risk of impending death SG will be more 
suitable [82].  
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Papers using chained approaches for valuation reported some challenges with the most common relating 
to the choice of the anchor HS. The intermediate HS plays a central role in the chained approach. In 
selecting an intermediate HS, it is important that the HS can be broadly applied and compared across 
different scenarios. . Finally, very few studies reported on aspects such as validity and reliability 
(Appendix D)  
Previous research 
A previous study reviewed the techniques used for THS valuations for cost utility analysis (CUA) [30]. 
However, the study focused on the general advantages and disadvantages of each technique, rather than 
systematically reviewing the methods which had actually been used in practice. A study by Brazier et 
al.[47] examined the conventional methods used for the valuation of HS, however, the study included all 
HS and did not specifically focus on the issues relating to the valuation of THS. 
The current study adds to the existing literature by systematically investigating which methods have been 
used to value THS and exploring wider aspects such  the justification for choosing a method and the 
challenges encountered. These issues have not been addressed in previous studies.  
Strengths and weaknesses  
The main strength of this review is that it is the first that has explicitly assessed the different techniques 
used for THS valuation in the literature in terms of the technique used, the justification of the choice of 
technique and the challenges highlighted by the study authors. Another strength is the extensive and 
systematic search for relevant studies. The inclusion of a broad range of study types without any 
restrictions on the year of publication allowed a deep assessment of the approaches that have been used 
previously to value THS. The use of an adapted checklist [48] to inform the analysis is also a strength. 
This is the first time such a criteria has been used for adapted methods of HS valuation.  
However, as is expected in any study, there were also limitations associated with the review. The scarcity 
of selected papers that reported on the feasibility, validity and reliability of their techniques made it difficult 
to assess the robustness of the approaches used. There was not sufficient evidence in the papers to 
draw conclusions regarding validity and reliability of adapted methods. However much of the discussion 
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about the use of adapated methods relates to their feasibility and the papers’ findings show that these 
methods are feasible in a wide range of population groups.A second weakness relates to study selection; 
some studies did not explicitly state that the condition they were assessing included THS, thus a 
judgement needed to be made by the authors of this review. This might have led to some papers being 
missed. Finally, a pragmatic decision was made about search terms used.  We scoped, consulted experts 
and refined terms and some terms like ‘acute’ were considered but ultimately deemed unhelpful to the 
review. 
Implication for current practice and future research 
This review has highlighted the methodological challenges and lack of attention given to the valuation of 
THS. Nonetheless, it has also identified a combination of approaches that have been successfully used 
for the valuation of such outcomes. 
There is a need for more research on the appropriate use of THS techniques on the reliabilty and validity 
of the techniques. The area is still sparsely explored with most of the literature published more than 15 
years ago, presumably under the assumption that the discipline has matured to reach equilibrium given 
the requirement of decision making bodies to use QALYs [5]. But the clinical areas that are currently 
devoid of appropriate HSUVs primarily because of the presence of THS need attention in order to 
appropriately inform robust resource allocation decisions [25]. Criteria for the quality appraisal of methods 
adapted specifically for THS measurement also needs attention. 
Conclusions 
This review has shown that in measuring HS utilities for different conditions the majority of studies 
employed more than one technique.  There is no clear agreement on the most methodologically robust 
approach to valuing THS. Valuation is complex in terms of anchoring, and there is currently mixed and 
incomplete evidence on the level of comprehension by respondents. Finally, important issues relating to 
the validity, practicality and reliability of the techniques used, were not adequately covered by  most of the 
studies identified.   
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